Direct Oral Anticoagulants (DOACs)
7
3
4
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
Impact of Treatment With Oral Anticoagulants of Patients With Fractures of the Upper End of the Femur
Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs
LED Application Following Dental Extraction in Patients Taking Direct Oral Anticoagulants.
OBServaToIre interNational Des Patients AnTiphospholipidEs traités Par Anticoagulants Oraux Directs